Department of Physiological Chemistry, University of Veterinary Medicine Hannover, Germany.
Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.
Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):817-826. doi: 10.1016/j.bbadis.2016.12.017. Epub 2017 Jan 3.
BACKGROUND & AIMS: Congenital sucrase-isomaltase deficiency (CSID) is a genetic disorder associated with mutations in the sucrase-isomaltase (SI) gene. The diagnosis of congenital diarrheal disorders like CSID is difficult due to unspecific symptoms and usually requires invasive biopsy sampling of the intestine. Sequencing of the SI gene and molecular analysis of the resulting potentially pathogenic SI protein variants may facilitate a diagnosis in the future. This study aimed to categorize SI mutations based on their functional consequences.
cDNAs encoding 13 SI mutants were expressed in COS-1 cells. The molecular pathogenicity of the resulting SI mutants was defined by analyzing their biosynthesis, cellular localization, structure and enzymatic functions.
Three biosynthetic phenotypes for the novel SI mutations were identified. The first biosynthetic phenotype was defined by mutants that are intracellularly transported in a fashion similar to wild type SI and with normal, but varying, levels of enzymatic activity. The second biosynthetic phenotype was defined by mutants with delayed maturation and trafficking kinetics and reduced activity. The third group of mutants is entirely transport incompetent and functionally inactive.
The current study unraveled CSID as a multifaceted malabsorption disorder that comprises three major classes of functional and trafficking mutants of SI and established a gradient of mild to severe functional deficits in the enzymatic functions of the enzyme.
This novel concept and the existence of mild consequences in a number of SI mutants strongly propose that CSID is an underdiagnosed and a more common intestinal disease than currently known.
先天性蔗糖-异麦芽糖酶缺乏症(CSID)是一种与蔗糖-异麦芽糖酶(SI)基因突变相关的遗传疾病。由于先天性腹泻疾病的症状不具有特异性,因此诊断较为困难,通常需要对肠道进行侵入性活检取样。对 SI 基因进行测序和对潜在致病的 SI 蛋白变异体进行分子分析,可能有助于未来的诊断。本研究旨在根据其功能后果对 SI 突变进行分类。
在 COS-1 细胞中表达了 13 种 SI 突变体的 cDNA。通过分析其生物合成、细胞定位、结构和酶功能,来确定由此产生的 SI 突变体的分子致病性。
确定了三种新型 SI 突变的生物合成表型。第一个生物合成表型由类似于野生型 SI 的方式在细胞内运输的突变体定义,这些突变体具有正常但不同程度的酶活性。第二个生物合成表型由成熟和运输动力学延迟以及活性降低的突变体定义。第三组突变体完全不能运输且功能失活。
本研究揭示 CSID 是一种多方面的吸收不良疾病,由 SI 的三种主要功能和运输突变体组成,并确定了该酶酶功能中从轻度到重度的功能缺陷梯度。
该新概念和大量 SI 突变体存在轻度后果强烈表明 CSID 是一种未被充分诊断的、比目前已知更为常见的肠道疾病。